Atea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Misses Estimates By $0.05 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) posted its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05), Zacks reports.

Atea Pharmaceuticals Stock Down 0.3 %

Shares of AVIR stock opened at $3.00 on Friday. The stock has a market cap of $253.39 million, a PE ratio of -1.45 and a beta of 0.18. Atea Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $4.18. The business has a 50-day simple moving average of $3.16 and a 200-day simple moving average of $3.35.

Insider Buying and Selling

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now directly owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 17.80% of the stock is owned by corporate insiders.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.